Oxford Immunotec Global PLC (NASDAQ:OXFD) Issues Earnings Results

Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32), Morningstar.com reports. The company had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The company’s revenue for the quarter was up 35.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) earnings per share.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 4.51% during mid-day trading on Friday, hitting $15.05. 200,355 shares of the stock were exchanged. The company’s market capitalization is $347.29 million. The firm has a 50-day moving average price of $16.78 and a 200 day moving average price of $15.22. Oxford Immunotec Global PLC has a 12-month low of $9.49 and a 12-month high of $19.51.

Several research firms have commented on OXFD. Piper Jaffray Companies reissued a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. ValuEngine raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. Finally, Cowen and Company decreased their target price on shares of Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Thursday. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $20.25.

In related news, VP Elizabeth M. Keiley sold 4,085 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the transaction, the vice president now directly owns 25,393 shares of the company’s stock, valued at $381,148.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Peter Edwardson sold 22,371 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $17.70, for a total transaction of $395,966.70. Following the completion of the transaction, the chief operating officer now directly owns 102,644 shares of the company’s stock, valued at $1,816,798.80. The disclosure for this sale can be found here. Insiders sold 126,195 shares of company stock valued at $2,073,682 over the last three months. 7.58% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in OXFD. Neuberger Berman Group LLC boosted its position in Oxford Immunotec Global PLC by 143.6% in the first quarter. Neuberger Berman Group LLC now owns 134,229 shares of the company’s stock worth $2,079,000 after buying an additional 79,129 shares during the period. American International Group Inc. boosted its position in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares during the period. TFS Capital LLC boosted its position in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock worth $219,000 after buying an additional 2,337 shares during the period. Denver Investment Advisors LLC boosted its position in Oxford Immunotec Global PLC by 47.5% in the first quarter. Denver Investment Advisors LLC now owns 30,880 shares of the company’s stock worth $478,000 after buying an additional 9,949 shares during the period. Finally, Parkwood LLC bought a new position in Oxford Immunotec Global PLC during the first quarter worth approximately $176,000. 84.96% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Oxford Immunotec Global PLC (NASDAQ:OXFD) Issues Earnings Results” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/08/19/oxford-immunotec-global-plc-nasdaqoxfd-issues-earnings-results-updated-updated.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Earnings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit